Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $19.21 in the prior trading day, Alignment Healthcare Inc (NASDAQ: ALHC) closed at $18.91, down -1.56%. In other words, the price has decreased by -$1.56 from its previous closing price. On the day, 2.09 million shares were traded. ALHC stock price reached its highest trading level at $19.46 during the session, while it also had its lowest trading level at $18.83.
Ratios:
Our goal is to gain a better understanding of ALHC by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 2.04 whereas as Long-Term Debt/Eq ratio is at 2.04.
On October 14, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $21.
KeyBanc Capital Markets Upgraded its Sector Weight to Overweight on August 25, 2025, while the target price for the stock was maintained at $21.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 10 ’25 when General Atlantic (ALN HLTH), L bought 11,119,494 shares for $18.57 per share.
JEK TRUST U/A DTD 02/08/2021 bought 540,000 shares of ALHC for $10,373,400 on Dec 10 ’25. On Dec 08 ’25, another insider, JOYCE CHRISTOPHER J, who serves as the Chief Legal and Admin. Officer of the company, sold 19,706 shares for $19.33 each. As a result, the insider received 380,905 and left with 323,886 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALHC now has a Market Capitalization of 3783734784 and an Enterprise Value of 3469312768. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.04 while its Price-to-Book (P/B) ratio in mrq is 23.36. Its current Enterprise Value per Revenue stands at 0.954 whereas that against EBITDA is 97.843.
Stock Price History:
The Beta on a monthly basis for ALHC is 1.16, which has changed by 0.72751796 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, ALHC has reached a high of $21.06, while it has fallen to a 52-week low of $10.18. The 50-Day Moving Average of the stock is 8.19%, while the 200-Day Moving Average is calculated to be 17.80%.
Shares Statistics:
The stock has traded on average 3.07M shares per day over the past 3-months and 2499450 shares per day over the last 10 days, according to various share statistics. A total of 199.99M shares are outstanding, with a floating share count of 161.46M. Insiders hold about 19.31% of the company’s shares, while institutions hold 87.23% stake in the company. Shares short for ALHC as of 1764288000 were 15223105 with a Short Ratio of 4.97, compared to 1761868800 on 13767170. Therefore, it implies a Short% of Shares Outstanding of 15223105 and a Short% of Float of 11.66.
Earnings Estimates
The market rating of Alignment Healthcare Inc (ALHC) is currently shaped by the ongoing analysis conducted by 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.11, with high estimates of $0.11 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.28 and $0.11 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.38, with 4.0 analysts recommending between $0.46 and $0.26.
Revenue Estimates
11 analysts predict $1B in revenue for. The current quarter. It ranges from a high estimate of $1.01B to a low estimate of $980M. As of. The current estimate, Alignment Healthcare Inc’s year-ago sales were $701.24MFor the next quarter, 11 analysts are estimating revenue of $1.22B. There is a high estimate of $1.28B for the next quarter, whereas the lowest estimate is $1.17B.
A total of 11 analysts have provided revenue estimates for ALHC’s current fiscal year. The highest revenue estimate was $3.94B, while the lowest revenue estimate was $3.9B, resulting in an average revenue estimate of $3.94B. In the same quarter a year ago, actual revenue was $2.7BBased on 11 analysts’ estimates, the company’s revenue will be $5.09B in the next fiscal year. The high estimate is $5.39B and the low estimate is $4.93B.
